Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $56.50 Consensus Target Price from Brokerages

Key Points

• Establishment Labs Holdings Inc. has received a consensus rating of "Moderate Buy" from six brokerages, with five recommending a buy and one holding the stock, with a 12-month price objective averaging $56.50.
• Institutional investors own approximately 72.91% of Establishment Labs' shares, indicating strong institutional interest in the company.
• The company's recent quarterly earnings revealed a reported loss of ($0.57) per share, which was slightly higher than the consensus estimate, but revenue increased by 16.1% year-over-year.

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $56.50.

ESTA has been the topic of a number of research analyst reports. Canaccord Genuity Group initiated coverage on shares of Establishment Labs in a report on Wednesday, August 20th. They issued a "buy" rating and a $60.00 price target on the stock. Wall Street Zen cut shares of Establishment Labs from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Needham & Company LLC reiterated a "buy" rating and issued a $48.00 price target on shares of Establishment Labs in a report on Friday, June 13th. Mizuho increased their price target on Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. Finally, Citigroup increased their price target on Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a report on Wednesday, July 9th.

Institutional Trading of Establishment Labs

Several large investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC increased its holdings in Establishment Labs by 7.2% in the 1st quarter. Nantahala Capital Management LLC now owns 1,774,044 shares of the company's stock valued at $72,390,000 after purchasing an additional 119,574 shares in the last quarter. Tyro Capital Management LLC lifted its holdings in Establishment Labs by 0.3% in the 2nd quarter. Tyro Capital Management LLC now owns 1,066,721 shares of the company's stock worth $45,560,000 after buying an additional 2,835 shares in the last quarter. Bamco Inc. NY lifted its holdings in Establishment Labs by 21.5% in the 2nd quarter. Bamco Inc. NY now owns 907,537 shares of the company's stock worth $38,761,000 after buying an additional 160,755 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in Establishment Labs by 2.1% in the 2nd quarter. William Blair Investment Management LLC now owns 865,244 shares of the company's stock worth $36,955,000 after buying an additional 17,855 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its holdings in Establishment Labs by 7.4% in the 1st quarter. Rice Hall James & Associates LLC now owns 827,423 shares of the company's stock worth $33,763,000 after buying an additional 56,756 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Trading Down 1.7%

Shares of ESTA traded down $0.63 during mid-day trading on Thursday, reaching $36.84. The company had a trading volume of 241,652 shares, compared to its average volume of 252,313. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -12.08 and a beta of 0.85. The firm has a fifty day simple moving average of $40.67 and a 200-day simple moving average of $37.94. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $50.85. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 9.71.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.03). The company had revenue of $51.30 million during the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The firm's revenue for the quarter was up 16.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.62) EPS. Establishment Labs has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Establishment Labs will post -2.41 EPS for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.